Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer

Stem Cells
P RiikonenM Perkkiö

Abstract

We evaluated granulocyte colony-stimulating factor (G-CSF) as an adjunct to courses of conventional chemotherapy in 16 children with cancer. One course followed by G-CSF (20 episodes) was compared to identical courses without G-CSF (20 episodes) in the same patients. The mean duration of G-CSF therapy was 8.8 (5-13) days. The periods of neutropenia (4.8 days versus 16.5 days; p < 0.0001), days of hospitalization for febrile neutropenia (13 days versus 65 days; p = 0.02) and days on broad-spectrum antibiotics (13 days versus 95 days; p = 0.003) were significantly reduced. With the use of G-CSF the profound neutropenia could be prevented in 11 (55%) episodes. There were two episodes of fever and neutropenia in the G-CSF group as compared to 10 febrile neutropenias in the control group (p = 0.04). G-CSF was well tolerated and did not cause additional expenses when compared to the expenses needed for the treatment of febrile neutropenias. The cost benefit analyses showed that through using G-CSF a savings was realized in the amount of U.S. $20,650 for 20 cycles of chemotherapy, i.e., U.S. $1,033/chemotherapy cycle. We conclude that the use of G-CSF was efficacious and did not increase the total costs of therapy.

References

Jul 2, 1992·The New England Journal of Medicine·G J Lieschke, A W Burgess
Jul 9, 1992·The New England Journal of Medicine·G J Lieschke, A W Burgess
Oct 1, 1992·Annals of Medicine·S O Lie, G Gustafsson
Jan 1, 1991·The American Journal of Pediatric Hematology/oncology·W L Furman, W M Crist
Jan 1, 1991·The Journal of Infectious Diseases·D Kalman, S L Barriere
Jun 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W L FurmanV M Santana
Nov 1, 1993·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E Roilides, P A Pizzo
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S P HungerS S Donaldson
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D M GreenS Shochat
Aug 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R GeyerJ L Finlay

❮ Previous
Next ❯

Citations

Feb 14, 2002·British Journal of Haematology·Thomas Lehrnbecher, Karl Welte
Apr 20, 2001·Paediatric Drugs·L M Wagner, W L Furman
Apr 1, 2009·Expert Review of Hematology·Thomas Lehrnbecher, Ursula Creutzig
Mar 19, 2003·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Dennis W RaischMichael L Graham
Apr 7, 1996·PharmacoEconomics·G Dranitsaris
Feb 1, 1997·Journal of Surgical Oncology·T J GarrettD W Kinne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.